2 active not recruiting, 1 completed, 1 recruiting. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Active not recruiting 2, Completed 1, Recruiting 1 |
Follow Clear Cell Carcinoma: new trials by email Literature Review of Clear Cell Carcinoma trials Research Report on Clear Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy 3 cycles chemotherapy instead of 6 cycles chemotherapy, 6 cycles chemotherapy - Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Recruiting | North Eastern German Society of Gynaecological Oncology | 640 | 2024-10-11 | 2026-10-23 |
| A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study) Dostarlimab, Bevacizumab, Doxorubicin - Ovarian Neoplasms, Endometrial Neoplasms | Phase 2 | Active not recruiting | Yonsei University | 198 | 2024-01-22 | 2026-11-02 |
| A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies vudalimab - Ovarian Cancer, Clear Cell Carcinoma | Phase 2 | Active not recruiting | Xencor, Inc. | 170 | 2022-07-21 | 2025-02-07 |
| A Study of Nivolumab in Selected Uterine Cancer Patients Nivolumab - Uterine Cancer, Endometrial Carcinoma | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 35 | 2017-08-03 | 2024-12-27 |
Adenocarcinoma, Clear Cell (4) · Endometrial Neoplasms (3) · Ovarian Neoplasms (3) · Fallopian Tube Neoplasms (2) · Uterine Cervical Neoplasms (2) · Carcinosarcoma (1) · Leiomyosarcoma (1) · Prostatic Neoplasms (1) · Uterine Neoplasms (1) · Vaginal Neoplasms (1) · Vulvar Neoplasms (1)
Adenocarcinoma (4) · Carcinoma (4) · Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4) · Genital Diseases (4) · Genital Diseases, Female (4) · Genital Neoplasms, Female (4) · Neoplasms (4) · Neoplasms by Histologic Type (4) · Neoplasms by Site (4) · Neoplasms, Glandular and Epithelial (4) · Urogenital Diseases (4) · Urogenital Neoplasms (4) · Adnexal Diseases (3) · Endocrine Gland Neoplasms (3)
Bevacizumab (1) · Doxorubicin (1) · Gemcitabine (1) · Nivolumab (1) · Paclitaxel (1) · dostarlimab (1) · liposomal doxorubicin (1)
Memorial Sloan Kettering Cancer Center (1) · North Eastern German Society of Gynaecological Oncology (1) · Xencor, Inc. (1) · Yonsei University (1)
United States (2) · Australia (1) · Austria (1) · Belgium (1) · Czechia (1) · Germany (1) · Hong Kong (1) · Italy (1) · Japan (1) · Singapore (1) · South Korea (1) · Spain (1) · Taiwan (1) · United Kingdom (1)
Claire Friedman, MD (1) · Jalid Sehouli, Prof. Dr. med. (1) · Jolene Shorr (1)